Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A monogenic disease that has material basis in mutation in the CDKL5 gene.
No HPO annotations are available for this condition.
CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy (DEE) characterized by severe early-onset epilepsy and motor, cognitive, visual, and autonomic disturbances [, , , , , , , ]. Movement disorders include chorea, dystonia, and stereotypical hand and leg movements . Cardiac involvement is nonspecific . Because the full spectrum of phenotypic severity is still emerging, especially given the possibility of mosaicism (in males and females) and the potential for skewed X-chromosome inactivation (in females), an individual with a de novo CDKL5 pathogenic variant may have a mild phenotype (for example, minimal epilepsy and global developmental delays). To date, approximately 500 individuals have been identified with CDD .
For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth as it determines clinical care . Diagnostic criteria for CDKL5 deficiency disorder (CDD) have been proposed .
CDD should be suspected in females and males with motor and cognitive developmental delays and epilepsy with onset in the first year of life (developmental delays and early-onset epilepsy constitute the minimal clinical diagnostic criteria proposed by ). Note: (1) Although females are more commonly affected than males with this X-linked disorder, the severity of manifestations in affected females and males can be equivalent.
No approved treatments are currently available for CDKL5 disorder. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for CDKL5 disorder, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for CDKL5 disorder. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. In general, annual assessments by a medical home/primary care physician and specialists are needed.
Table 7.
CDKL5 Deficiency Disorder: Recommended Surveillance
System/Concern | Evaluation | Frequency
6 clinical trials registered, 1 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 2 PHASE3, 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05558371](https://clinicaltrials.gov/study/NCT05558371) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 11:03 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Common questions about CDKL5 disorder
Source: GeneReviews — "CDKL5 Deficiency Disorder"
Source: GeneReviews — "CDKL5 Deficiency Disorder"
Table 3. Developmental and Epileptic Encephalopathies in the Differential Diagnosis of CDKL5 Deficiency Disorder
Gene(s) | Disorder | MOI |
|---|---|---|
ARX | ARX-related DEE (OMIM 308350) | XL FOXG1 |
GABRA1 | GABRA1-related DEE (OMIM 615744) | AD |
GABRB3 | GABRB3-related DEE (OMIM 617113) | AD |
GABRG2 | GABRG2-related DEE (OMIM 618396) | AD GRIN2A |
KCNQ2 | KCNQ2-related developmental epileptic encephalopathy (OMIM 613720) | AD KCNT1 |
MECP2 | MECP2 classic Rett syndrome (See MECP2 Disorders.) | XL MECP2 duplication syndrome |
PCDH19 | PCDH19-related DEE (OMIM 300088) | XL SCN1A |
SCN2A | SCN2A-related DEE (OMIM 613721) | AD SCN8A |
SLC2A1 | Classic glucose transporter type 1 deficiency syndrome (See Glucose Transporter Type 1 Deficiency Syndrome.) | AD(AR)1 STXBP1 |
Source: GeneReviews — "CDKL5 Deficiency Disorder"
Biomarker and diagnostic research for CDKL5 disorder has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
allopurinol | allopurinol | Jainu Jogani | 2024 | — | Designated |
Balipodect | Balipodect | Takeda Development Center Americas, Inc. | 2019 | — | Withdrawn |
International consensus recommendations for the assessment and management of individuals with CDKL5 deficiency disorder (CDD) have been published (full text). The management of individuals with CDD is complex and requires multiple specialty appointments; referral to a CDKL5 Center of Excellence may allow families to more easily coordinate care for affected individuals (to date, ten CDKL5 Centers of Excellence have been established in the United States).
To establish the extent of disease and needs in an individual diagnosed with CDD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
CDKL5 Deficiency Disorder: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measurement of OFC, length, weight | • Smaller OFC is assoc w/ severity of disorder.1
Poor weight gain can reflect nutritional status.
| Eval of epilepsy by neurologist or epileptologist | • EEG to assess EEG background, epileptiform activity, seizure type correlate w/clinical semiology
Prolonged video EEGs may be required to characterize spells of unclear etiology or rule out subclinical status epilepticus.
Eval of movement disorders | To characterize movement disorder, if present, ascertain effect on gross fine motor skills
Ophthalmologic/
| Ophthalmologist | Assess for visual acuity, abnormal ocular movement, refractive errors, strabismus
Source: GeneReviews — "CDKL5 Deficiency Disorder"
Several therapies have been investigated or are ongoing for CDD including the following:
Soticlestat/TAK935 (NCT03694275)
Ataluren (NCT02758626)
Fenfluramine (NCT03861871, NCT05064878)
Canabidiol
Ketogenic diet
Vagal nerve stimulation
Protein and gene replacement therapies have been proposed.
Clinical trials and registries assessing natural history and outcome measures are ongoing (NCT05558371, NCT05373719, NCT04486768). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "CDKL5 Deficiency Disorder"
6 trials found
| Measurement of OFC, length, weight | Annually, or more frequently as required for mgmt
| Monitor those w/seizures as clinically indicated. | At each annual visit
Assess for new manifestations such as seizures, changes in tone, movement disorders. | At each visit
| • Measurement of growth parameters
Eval of nutritional status safety of oral intake
Eval of feeding time
| Monitor developmental progress educational needs.
Neurobehavioral/
| Assessment for sleep, anxiety, ADHD, ASD, aggression, self-injury
| Monitor for feeding, nutrition, constipation, GERD.
| Monitor for evidence of aspiration respiratory insufficiency.
| • Physical medicine, OT/PT assessment of mobility, self-help skills
Assessment of large joint mobility (e.g., hip surveillance)
Clinical eval of spine
Spine radiograph as needed to identify progressive scoliosis
Referral to orthopedist if Cobb angle 45 degrees for consideration of surgical correction
| At each annual visit
| Assess family need for social work support (e.g., palliative/respite care, home...
Source: GeneReviews — "CDKL5 Deficiency Disorder"
International CDKL5 Clinical Research Network
— |
University of Colorado, Denver |
RECRUITING |
[NCT04486768](https://clinicaltrials.gov/study/NCT04486768) | International CDKL5 Registry | — | University of Pennsylvania | UNKNOWN |
[NCT05249556](https://clinicaltrials.gov/study/NCT05249556) | Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old | PHASE3 | Immedica Pharma AB | NOT_YET_RECRUITING |
[NCT06448663](https://clinicaltrials.gov/study/NCT06448663) | Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD) | NA | University of Milan | UNKNOWN |
[NCT05064878](https://clinicaltrials.gov/study/NCT05064878) | A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | PHASE3 | Zogenix, Inc. | ACTIVE_NOT_RECRUITING |
93 publications have been identified in PubMed for CDKL5 disorder. Research spans Basic Science / Preclinical (37%), Review / Meta-Analysis (15%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 34 | 37% |
Research summaries | 14 | 15% |
Disease patterns and progression | 12 | 13% |
Patient case studies | 11 | 12% |
New treatment approaches | 10 | 11% |
Testing and diagnosis research | 7 | 8% |
Clinical study results | 3 | 3% |
Other research | 2 | 2% |
Higgins J (2026). [PMID: 41718488](https://pubmed.ncbi.nlm.nih.gov/41718488/). *Epilepsia Open*. [Basic Science / Preclinical]
Coletti A (2026). [PMID: 42188286](https://pubmed.ncbi.nlm.nih.gov/42188286/). *Mar Drugs*. [Gene Therapy / Novel Therapeutics]
Li M (2026). [PMID: 41706882](https://pubmed.ncbi.nlm.nih.gov/41706882/). *Proc Natl Acad Sci U S A*. [Epidemiology / Natural History]
Shiohama T (2026). [PMID: 42193287](https://pubmed.ncbi.nlm.nih.gov/42193287/). *Biomedicines*. [Basic Science / Preclinical]
Leonard H (2026). [PMID: 41484992](https://pubmed.ncbi.nlm.nih.gov/41484992/). *J Neurodev Disord*. [Epidemiology / Natural History]
Boggio Bozzo S (2026). [PMID: 41807047](https://pubmed.ncbi.nlm.nih.gov/41807047/). *Life Sci Alliance*. [Basic Science / Preclinical]
Liogier d'Ardhuy X (2026). [PMID: 41531035](https://pubmed.ncbi.nlm.nih.gov/41531035/). *Epilepsia*. [Epidemiology / Natural History]
Zubiete-Franco I (2026). [PMID: 42167577](https://pubmed.ncbi.nlm.nih.gov/42167577/). *J Biol Chem*. [Basic Science / Preclinical]
Basu S (2026). [PMID: 41266835](https://pubmed.ncbi.nlm.nih.gov/41266835/). *Indian J Pediatr*. [Other]
Keeley J (2026). [PMID: 40900005](https://pubmed.ncbi.nlm.nih.gov/40900005/). *J Child Neurol*. [Diagnostic / Biomarker]